Home/Pipeline/Internal Solid Tumor Program(s)

Internal Solid Tumor Program(s)

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Chimera Bioengineering

About Chimera Bioengineering

Chimera Bioengineering is pioneering a novel approach to cell therapy by developing CAR-T cells with precisely controlled genetic programming. Their core technology, the GOLD PLATFORM™, includes components like MERCURY™ for tuning CAR expression and GOLD CONTROL™ for regulating therapeutic payloads, addressing key challenges of insufficient activity and excessive toxicity in current cell therapies. The company is independently advancing several solid tumor and blood cancer programs toward clinical trials while seeking strategic collaborations to validate and expand its platform. Their mission is to transform the promise of cell therapies into effective, safe treatments that restore dignity to cancer patients.

View full company profile

Therapeutic Areas

Oncology Solid Tumors Blood Cancers

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active